Increase in Drug Spending in Canada Due to Extension of Data Protection for Biologics: A Descriptive Study.

The potential impact on drug expenditures of a two-year extension in data protection is highly variable. Possible increases in spending on biologics strengthen the rationale for a national pharmacare plan where monopsony buying power would help to control drug prices overall and offset increased spending on biologics.